Alere Acquires Epocal for USD 166 Million
By LabMedica International staff writers Posted on 18 Feb 2013 |
Alere Inc. (Waltham, MA, USA) has acquired Epocal, Inc., (Ottawa, Canada) a provider of technologies that support blood gas and electrolyte testing at the point of care (POC).
In 2009, the two companies entered into an agreement for Alere to acquire all of Epocal’s issued and outstanding equity securities, contingent upon the achievement of gross margin and other financial milestones on or before October 31, 2014. The company did not disclose what those specific milestones were.
By developing new capabilities in near-patient diagnosis, monitoring, and health information solutions, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology, and diabetes.
Commenting on the acquisition, Alere CEO, Ron Zwanziger, stated, “Through its unique combination of novel diagnostic parameters and wireless-enabled technology, Epocal has set new standards in helping healthcare practitioners in critical settings deliver better patient outcomes, all the while establishing clinical efficiencies. These achievements are core to Alere’s broader mission of empowering individuals and their physicians with data that drive more responsive decision making and improved health outcomes, and we welcome Epocal into the Alere family.”
Related Links:
Alere
Epocal
In 2009, the two companies entered into an agreement for Alere to acquire all of Epocal’s issued and outstanding equity securities, contingent upon the achievement of gross margin and other financial milestones on or before October 31, 2014. The company did not disclose what those specific milestones were.
By developing new capabilities in near-patient diagnosis, monitoring, and health information solutions, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology, and diabetes.
Commenting on the acquisition, Alere CEO, Ron Zwanziger, stated, “Through its unique combination of novel diagnostic parameters and wireless-enabled technology, Epocal has set new standards in helping healthcare practitioners in critical settings deliver better patient outcomes, all the while establishing clinical efficiencies. These achievements are core to Alere’s broader mission of empowering individuals and their physicians with data that drive more responsive decision making and improved health outcomes, and we welcome Epocal into the Alere family.”
Related Links:
Alere
Epocal
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus